- Home
- UNCY vs ACHV Comparison
UNCY vs ACHV Comparison
Compare UNCY & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- ACHV
- Stock Information
- Founded
- UNCY 2016
- ACHV N/A
- Country
- UNCY United States
- ACHV Canada
- Employees
- UNCY 22
- ACHV N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- UNCY Health Care
- ACHV Health Care
- Exchange
- UNCY Nasdaq
- ACHV Nasdaq
- Market Cap
- UNCY 71.3M
- ACHV 72.5M
- IPO Year
- UNCY 2021
- ACHV N/A
- Fundamental
- Price
- UNCY $0.61
- ACHV $3.85
- Analyst Decision
- UNCY Strong Buy
- ACHV Strong Buy
- Analyst Count
- UNCY 4
- ACHV 3
- Target Price
- UNCY $6.38
- ACHV $14.33
- AVG Volume (30 Days)
- UNCY 889.6K
- ACHV 234.9K
- Earning Date
- UNCY 05-14-2025
- ACHV 05-13-2025
- Dividend Yield
- UNCY N/A
- ACHV N/A
- EPS Growth
- UNCY N/A
- ACHV N/A
- EPS
- UNCY N/A
- ACHV N/A
- Revenue
- UNCY N/A
- ACHV N/A
- Revenue This Year
- UNCY N/A
- ACHV N/A
- Revenue Next Year
- UNCY $1,422.24
- ACHV N/A
- P/E Ratio
- UNCY N/A
- ACHV N/A
- Revenue Growth
- UNCY N/A
- ACHV N/A
- 52 Week Low
- UNCY $0.20
- ACHV $1.84
- 52 Week High
- UNCY $0.96
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- UNCY 49.67
- ACHV 70.30
- Support Level
- UNCY $0.56
- ACHV $2.89
- Resistance Level
- UNCY $0.62
- ACHV $3.32
- Average True Range (ATR)
- UNCY 0.05
- ACHV 0.25
- MACD
- UNCY 0.00
- ACHV 0.07
- Stochastic Oscillator
- UNCY 74.83
- ACHV 91.47
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.